About Zhejiang Daoer Biological Technology
Zhejiang Daoer Biological Technology is a company based in Hangzhou (China) founded in 2014. Zhejiang Daoer Biological Technology has raised $14.94 million across 2 funding rounds from investors including Kaitai Capital and Zhejiang Huarui Investment Holdings. Zhejiang Daoer Biological Technology operates in a competitive market with competitors including Ardelyx, Carmot, DermBiont, Inozyme Pharma and Kriya Therapeutics, among others.
- Headquarter Hangzhou, China
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$14.94 M (USD)
in 2 rounds
-
Latest Funding Round
$14.94 M (USD), Series A
Nov 03, 2020
-
Investors
Kaitai Capital
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Zhejiang Daoer Biological Technology
Zhejiang Daoer Biological Technology has successfully raised a total of $14.94M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $14.94 million completed in November 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Zhejiang Daoer Biological Technology
Zhejiang Daoer Biological Technology has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Kaitai Capital and Zhejiang Huarui Investment Holdings.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Kaitai Capital is engaged in innovation investment management services.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Zhejiang Daoer Biological Technology
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Zhejiang Daoer Biological Technology
Investment portfolio details for Zhejiang Daoer Biological Technology
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Zhejiang Daoer Biological Technology
Detailed financials for Zhejiang Daoer Biological Technology
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Zhejiang Daoer Biological Technology Comparisons
Peer comparison for Zhejiang Daoer Biological Technology
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Zhejiang Daoer Biological Technology
Zhejiang Daoer Biological Technology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ardelyx, Carmot, DermBiont, Inozyme Pharma and Kriya Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
Disease-modifying therapies for metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
Microbial therapeutics for skin diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of treatments for rare and debilitating metabolic diseases
|
|
| Locked | Locked | Locked |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| Locked | Locked | Locked |
Therapeutics for infectious and autoimmune diseases are developed.
|
Detailed competitors of Zhejiang Daoer Biological Technology
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Zhejiang Daoer Biological Technology
Complete news archive for Zhejiang Daoer Biological Technology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Zhejiang Daoer Biological Technology
Zhejiang Daoer Biological Technology was founded in 2014 and raised its 1st funding round 5 years after it was founded.
Zhejiang Daoer Biological Technology is headquartered in Hangzhou, China. It is registered at Hangzhou, Zhejiang, China.
Zhejiang Daoer Biological Technology is a funded company, having raised a total of $14.94M across 2 funding rounds to date.
Zhejiang Daoer Biologicals is developing protein therapies for metabolic diseases and cancers. The company has proprietary protein drug discovery platforms such as recombinant PEG-like xLONGylation platform, MultiBody platform, and AccuBody platform. The lead candidate, DR10601 is a dual agonist Fc fragment of human IgG4 targeting glucagon receptor and GLP-1 receptor. The candidate is being developed for NASH, obesity, and diabetes (preclinical stage). Also developing antibodies and enzymes for oncology and ophthalmology.
Zhejiang Daoer Biological Technology's top competitors include Ardelyx, Carmot and Vedanta Biosciences.
Zhejiang Daoer Biological Technology has 2 investors. Key investors include Kaitai Capital, and Zhejiang Huarui Investment Holdings.